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Abstract
Background: Highly pathogenic avian influenza virus (AIV) subtype H5N1 remains a threat to poultry. Duck enteritis
virus (DEV)-vectored vaccines expressing AIV H5N1 hemagglutinin (HA) may be viable AIV and DEV vaccine
candidates.
Methods: To facilitate the generation and further improvement of DEV-vectored HA(H5) vaccines, we first constructed
an infectious clone of DEV Chinese vaccine strain C-KCE (DEVC-KCE). Then, we generated a DEV-vectored HA(H5) vaccine
(DEV-H5(UL55)) based on the bacterial artificial chromosome (BAC) by inserting a synthesized HA(H5) expression
cassette with a pMCMV IE promoter and a consensus HA sequence into the noncoding area between UL55 and
LORF11. The immunogenicity and protective efficacy of the resulting recombinant vaccine against DEV and AIV H5N1
were evaluated in both ducks and chickens.
Results: The successful construction of DEV BAC and DEV-H5(UL55) was verified by restriction fragment length
polymorphism analysis. Recovered virus from the BAC or mutants showed similar growth kinetics to their parental
viruses. The robust expression of HA in chicken embryo fibroblasts infected with the DEV-vectored vaccine was
confirmed by indirect immunofluorescence and western blotting analyses. A single dose of 106 TCID50 DEV-vectored
vaccine provided 100 % protection against duck viral enteritis in ducks, and the hemagglutination inhibition (HI)
antibody titer of AIV H5N1 with a peak of 8.2 log2 was detected in 3-week-old layer chickens. In contrast, only very
weak HI titers were observed in ducks immunized with 107 TCID50 DEV-vectored vaccine. A mortality rate of 60 %
(6/10) was observed in 1-week-old specific pathogen free chickens inoculated with 106 TCID50 DEV-vectored vaccine.
Conclusions: We demonstrate the following in this study. (i) The constructed BAC is a whole genome clone of
DEVC-KCE. (ii) The insertion of an HA expression cassette sequence into the noncoding area between UL55 and LORF11
of DEVC-KCE affects neither the growth kinetics of the virus nor its protection against DEV. (iii) DEV-H5(UL55) can
generate a strong humoral immune response in 3-week-old chickens, despite the virulence of this virus observed in
1-week-old chickens. (iv) DEV-H5(UL55) induces a weak HI titer in ducks. An increase in the HI titers induced by
DEV-vectored HA(H5) will be required prior to its wide application.
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Background
Duck enteritis virus (DEV), also known as duck plague,
is an important pathogen of ducks, which causes an
acute infectious disease with a very high mortality,
reaching up to 100 % in birds such as ducks, geese, and
wild waterfowls in the order Anseriformes [1, 2]. DEV
cases have been reported in many countries, including
the United states and China [3, 4]. DEV, also called ana-
tid herpesvirus 1, is a member of the Mardivirus genus
in the Alphaherpesvirinae subfamily of the Herpesviridae
family in the order Herpesvirales. The whole genomes of
attenuated and virulent strains of DEV have been
sequenced and annotated, which are approximately 158
kbp in length and contain 78 predicted open reading
frames (ORFs) of putative proteins [5, 6].
Bacterial artificial chromosomes (BACs) of a few
herpesviruses have been previously established [7–9].
Several mutant viruses have been generated by the BAC
mutagenesis protocol to study their pathology or their
potency as vectors [10–14]. The first DEV BAC was
constructed based on a virulent strain (V2085) isolated
from the dead ducks in an outbreak in Germany [2, 9].
A DEV-vectored vaccine harboring the hemagglutinin
(HA) of the highly pathogenic avian influenza virus
(AIV) subtype H5N1 was generated based on this BAC,
and robust expression of HA was confirmed in the in-
fected cells [9]. However, the safety of this vaccine
remains questionable owing to its development from a
virulent parental strain. Nevertheless, this proof-of-
principle study clearly demonstrated the potency of a
DEV-vectored vaccine expressing AIV HA as a candi-
date vaccine against AIV.
The AIV H5N1 has attracted considerable attention
worldwide owing to its high morbidity and mortality and
its potential to mutate into a highly pathogenic form
[15–19]. Birds are the main hosts of AIV, but human
infections of some strains have been reported. Migratory
birds are suspected to play an important role in the
transmission of AIV and have been related to several AI
outbreaks [20–22]. As the main reservoir of AIV H5N1,
ducks may serve as a constant source of viral transmis-
sion to chickens and other poultry [23]. Therefore,
effective control of AIV H5N1 infection in ducks is
critical for AI control in poultry and the prevention of
human infections.
Live virus-vectored vaccines based on herpesviruses have
been studied for decades, and their ability to induce both
robust cellular and humoral immunity has been docu-
mented [24–27]. Furthermore, several herpesvirus-vectored
vaccines have been licensed and are widely used in some
countries [28, 29]. In addition to an early study on the DEV
V2085 strain-vectored HA (H5N1) [9], another DEV-
vectored H5 vaccine (rDEV-us78HA) has been constructed
with the cosmid system using four overlapping DNAs of
the DEV genome, which provided strong protection against
both duck plague and highly pathogenic AIV H5N1 despite
eliciting a weak hemagglutination inhibition (HI) titer
[30, 31]. In this study, we generated an infectious clone of
DEV vaccine strain C-KCE (DEVC-KCE) and constructed a
DEV-vectored HA (AIV H5N1) vaccine based on the BAC
through the En Passant method [32]. This DEV-vectored
vaccine was constructed by inserting a synthesized HA
gene with consensus sequences from the most recently
updated AIV H5N1 strains into the noncoding area
between UL55 and LORF11. The stability and safety of
the DEV-vectored vaccine and its immunogenicity against
duck plague and AIV H5N1 were studied in both ducks
and chickens.
Results and discussion
Generation of recombinant DEV attenuated strain
harboring mini-F plasmid sequences
The mini-F sequences were inserted into the DEVC-KCE
genome firstly. Three days after the co-transfection of DNA
from DEVC-KCE and the BAC transfer vector plasmid
pDEVgc-pHA2, a recombinant DEVC-KCE harboring mini-F
plasmid sequences was successfully generated as indicated
by its production of green fluorescence under UV light
(488 nm; Fig. 1). Subsequently, a homogeneous population
of mini-F recombinant DEVC-KCE was obtained after three
rounds of picking and replating on chicken embryo fibro-
blasts (CEFs), and named DEVC-KCE-miniF.
Generation of an infectious clone of pDEVC-KCE
Next, we generated an infections clone of pDEVC-KCE. A
total of seven colonies with chloramphenicol resistance
were obtained after electroporation of DEVC-KCE-mini-F
DNA into Escherichia coli DH10B competent cells, one of
which, termed pDEVC-KCE, was selected for further restric-
tion fragment length polymorphism (RFLP) analysis.
Enzymatic digestion of pDEVC-KCE with BamH I and EcoR
I showed the expected patterns with slight differences
(Fig. 2), which might be caused by the differences between
the sequences of DEVC-KCE and the reference genome
DEV(VAC) (GenBank ID:EU082088.2). Then, the pDEVC-
KCE DNA from the Midi-prep was electroporated into E.
coli GS1783 competent cells to generate the infectious
clone Sa for further construction of mutants through the
En Passant method. RFLP patterns of Sa with BamH I and
EcoR I were exactly the same as that of pDEVC-KCE.
Generation of pDEVC-KCE-H5(UL55)
Following the successful generation of the DEVC-KCE clone
Sa, this clone was used in the En Passant method to gener-
ate a recombinant BAC clone (pDEVC-KCE-H5(UL55)KAN)
with both chloramphenicol and kanamycin resistance. The
HA expression cassette harboring a kanamycin resistance
gene was inserted through the first recombination with the
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DEVC-KCE BAC clone Sa. The kanamycin resistance gene
was successfully deleted from the HA expression cassette
through a second recombination to generate the DEV
recombinant BAC, named pDEVC-KCE-H5(UL55), which
harbored the HA expression cassette in the noncoding area
between UL55 and LORF11 (Fig. 3). RFLP analysis of
the BamH I digestion of these constructs showed that
DEVC-KCE BAC clone Sa lacked a band around 13
kbp (lane 1, Fig. 2a) while three bands of approxi-
mately 10 kbp, 4.8 kbp, and 2.7 kbp were observed in
pDEVC-KCE-H5(UL55)KAN (lane 2, Fig. 2a). Moreover,
pDEVC-KCE-H5(UL55) (lane 3, Fig. 2a) lacked a 4.8
kbp band, and instead had a band of approximately
3.8 kbp. These results are consistent with the ex-
pected patterns (Fig. 2b, lanes 1, 2, and 3), suggesting
the successful insertion of the HA expression cassette
and the deletion of kanamycin resistance gene. After
digestion with EcoR I, a band of approximately 5.5
kbp was observed in pDEVC-KCE-H5(UL55)KAN (lane
5, Fig. 2a) that was not observed in DEVC-KCE BAC
Fig. 2 RFLP of DEVC-KCE BAC clone Sa, of pDEVC-KCE-H5(UL55)KAN, and of pDEVC-KCE-H5(UL55). a DNA from DEVC-KCE BAC clone Sa (lanes 1 and 4) and
recombinant BACs of pDEVC-KCE-H5(UL55)KAN (lanes 2 and 5) and pDEVC-KCE-H5(UL55) (lanes 3 and 6) were prepared by mini-prep and digested with BamH
I (lanes 1–3) or EcoR I (lanes 4–6). The digests were separated by 0.8 % agarose gel electrophoresis for 16 h under 40v. Arrowheads highlight differences
between the lanes. b Predicted RFLP patterns of pDEVC-KCE-H5(UL55)KAN and pDEVC-KCE-H5(UL55) compared with BAC clone Sa. Size markers range from
2 to 20 kb. Lanes 1–3 show predicted BamH I digestion patterns of Sa, pDEVC-KCE-H5(UL55)KAN, and pDEVC-KCE-H5(UL55), respectively. Lanes 4–6 show
predicted EcoR I digestion patterns of Sa, pDEVC-KCE-H5(UL55)KAN, and pDEVC-KCE-H5(UL55), respectively. Predictions of these digestions were performed
using the DEV (VAC) whole genome sequences as a reference (GenBank ID:EU082088.2). M: DL 15,000 DNA Marker (Takara)
Fig. 1 Plaques of DEVC-KCE-mini-F and the parental DEVC-KCE virus. Images of DEVC-KCE-mini-F and DEVC-KCE plaques under UV excitation (left) and
phase contrast (right) are shown. Arrows show a plaque formed by DEVC-KCE-mini-F and arrowheads show a white plaque of parental DEVC-KCE
virus. Each panel represents a view of 200 × 200 μm in size
Wang et al. Virology Journal  (2015) 12:126 Page3of14
clone Sa or in pDEVC-KCE-H5(UL55) (lane 6, Fig. 2a).
However, pDEVC-KCE-H5(UL55) (lane 6, Fig. 2a) had
a unique band of approximately 4.5 kbp. These re-
sults support the successful insertion of a HA cassette
and the deletion of a kanamycin resistance gene, even
though they are slightly different from the expected
pattern (Fig. 2b). These differences might be due to
the different origins of DEVC-KCE and the reference
strain DEV(VAC), even though they both claimed to
be the Chinese commercial vaccine strain. The cor-
rect sequences of the inserted HA cassette were con-
firmed by sequencing.
Rescue of recombinant DEV from BAC and generation of
DEV mutants
After co-transfection of DNA from pDEVC-KCE and a
polymerase chain reaction (PCR) fragment that was
amplified using DEVC-KCE DNA as template and a pair
Fig. 3 Construction of recombinant pDEVC-KCE-H5(UL55). a A kanamycin resistance gene (sm) with a 40 bp homologous sequence (c) was
inserted into the Sac I restriction site (*) in the HA expression cassette, which was divided into two parts (HA Cas’ and HA Cas”). b The HA
expression cassette with the selective marker (sm) was inserted into the noncoding area between LORF11 and UL55 through the first
recombination to generate a recombinant BAC clone (pDEVC-KCE-H5(UL55)KAN) with both chloramphenicol and kanamycin resistance. c The
second recombination was performed to delete the kanamycin resistance gene and generate the final recombinant pDEVC-KCE-H5(UL55)-vectored
HA clone. Rectangles with the same type of shading indicate identical sequences. Scales in bp or kbp are provided
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of primers (DEV-HOMO1-for and DEV HOMO2-rev)
[9], nonfluorescent plaques were observed under UV
light (488 nm). A homogeneous population of viruses
was isolated by three rounds of picking and plating puri-
fication. The expected 3923 bp band was amplified by
PCR with primers (DEV gC flanking F and DEV gC
flanking R) and sequencing results showed that the
complete glycoprotein C (gC) gene was recovered from
the same place as in the parental virus. The resulting
gC-recovered DEV virus was termed DEVC-KCEgCR.
The DEVC-KCE-harboring HA, termed DEV-H5(UL55),
was successfully generated with gC recovered in a similar
way as for DEVC-KCEgCR using pDEVC-KCE-H5(UL55)
DNA. The DEV-H5(UL55) HA expression cassette was
amplified by PCR with primers (DEV ins H5 casse UL55 F
and DEV ins H5 casse UL55 R), and its correct insertion
was confirmed by sequencing with the 20 specific sequen-
cing primers (Table 1).
Stability and growth kinetics of mutant or gC-recovered
DEV
The DEV mutant with HA insertion, DEV-H5(UL55), was
replicated serially on CEFs for 20 passages (F20). To test
the stability of this virus, a fragment of approximately
3360–3390 bp was amplified with F20 virus DNA as a
template and a pair of primers (DEV ins H5 casse UL55 F
and DEV ins H5 casse UL55 R). The HA expression cas-
sette sequences were confirmed by sequencing, indicating
that the inserted HA expression cassette was stable for at
least 20 passages.
Multi-step growth kinetics of gC-recovered DEV virus
(DEVC-KCEgCR), made from pDEVC-KCE, and of DEV-
vectored HA recombinant virus (DEV-H5(UL55)), made
from pDEVC-KCE-H5(UL55), were compared with the
parental virus (DEVC-KCE) in three independent experi-
ments. No virus titers were detected at 12 h post-infection
(p.i.) in infected cell supernatants and the titers peaked
Table 1 Primers for PCR and sequencing
Primer Sequence
Kan ins’ H5(HA) F 5′-TTAgagctcCTCGCTGCAGGCGGCCGCTCTAGAACTCGTCGATCGCAGCGGGATGACGACGATAAGTAGGGATAAC-3′ a
Kan ins’ H5(HA) R 5′-CGCgagctcGGGTAATGCCAGTGTTACAACCA-3′ a
DEV ins H5 casse UL55 F 5′-CGACGGACTGCCAGTGAACGCTGAACAAGCTAGGACAATTCTAGTGGATCCCCCAACTCC-3′
DEV ins H5 casse UL55 R 5′-AAGTAAAGACCCAAGCTACTAACAGGGTATTTGGGTAATATTGTCGACTCTAGAGGATCCG-3′
DEV gC flanking F 5′-TTCGCCGTATTTACCAAATG-3′
DEV gC flanking R 5′-TGATTCCTTTTGTTCGGATA-3′
DEV H5(UL55) casse seq F1 5′-CTAGTGGATCCCCCAACTCC-3′
DEV H5(UL55) casse seq F2 5′-GTACATTGGGTCAATGGGAG-3′
DEV H5(UL55) casse seq F3 5′-AAGTACACTGCGTCAATAGG-3′
DEV H5(UL55) casse seq F4 5′-ACTTTCCAATGGGTTTTGCC-3′
DEV H5(UL55) casse seq F5 5′-GCTGATTAATGGGAAAGTAC-3′
DEV H5(UL55) casse seq F6 5′-CGATCATATTTGCATTGGTT-3′
DEV H5(UL55) casse seq F7 5′-TTGAAACACCTATTGAGCAG-3′
DEV H5(UL55) casse seq F8 5′-GGACATCAACACTAAACCAG-3′
DEV H5(UL55) casse seq F9 5′-GAATGTCCCAAATATGTGAA-3′
DEV H5(UL55) casse seq F10 5′-CTTAGAGAGGAGAATAGAGAAT-3′
DEV H5(UL55) casse seq R1 5′-TTGTCGACTCTAGAGGATCC-3′
DEV H5(UL55) casse seq R2 5′-CATCCATAAAGATAGACCAG-3′
DEV H5(UL55) casse seq R3 5′-ATGGAAGTCTAGAGTTCTCTC-3′
DEV H5(UL55) casse seq R4 5′-TAAAACCTGCTATAGCTCCA-3′
DEV H5(UL55) casse seq R5 5′-CGGTTTTAAAATTGTCCAGA-3′
DEV H5(UL55) casse seq R6 5′-TGGACATGCTGCACTCACCC-3′
DEV H5(UL55) casse seq R7 5′-TTTCCAGTATGTCTTGGGCA-3′
DEV H5(UL55) casse seq R8 5′-ATATGGAATTTCCAGGGGAA-3′
DEV H5(UL55) casse seq R9 5′-CCCAATGGAAAGTCCCTATT-3′
DEV H5(UL55) casse seq R10 5′-TCAGTGTACTTGGCTCCAAT-3′
a restriction enzyme sites added to primers are in bold lower case letters, and sequences in italics indicate additional bases that are not present in the original
DEV genome
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(around 106 plaque-forming units (pfu)/0.1 ml) at 72 h p.i.
for all virus strains. No significant differences were ob-
served between DEV-H5(UL55) and DEVC-KCE (p = 0.200
and p = 0.125 at 48 h and 72 h p.i., respectively) or between
DEVC-KCEgCR and DEVC-KCE (p = 0.122 and p = 0.055 at
48 h and 72 h p.i., respectively) (Fig. 4a).
The titers of viruses released from infected cells were
determined after three freeze–thaw cycles. Results re-
vealed a slightly lower titer of the gC revertant viruses
(DEVC-KCEgCR and DEV-H5(UL55)) compared with that
of the parental virus (DEVC-KCE). However, these differ-
ences were not significant between DEV-H5(UL55) and
DEVC-KCE (p = 0.094 and p = 0.154 at 48 h and 72 h p.i.,
respectively) or between DEVC-KCEgCR and DEVC-KCE
(p = 0.164 and p = 0.322 at 48 h and 72 h p.i., respect-
ively) (Fig. 4b). These results prove that the DEVC-KCE
BAC clone is a whole genome clone of the parental
virus and the genetic manipulation of DEV-vectored
HA during the En Passant recombination did not affect
the integrity of the genome. The results also show that
the insertion of a foreign gene expression cassette be-
tween the noncoding area of UL55 and LORF11 did not
affect either the growth kinetics of the virus or the
stability of the inserted sequences. These findings sup-
port the development of the constructed DEV-
H5(UL55) as a live vector vaccine candidate.
Expression of AIV HA by recombinant DEV-H5(UL55)
In indirect immunofluorescence (IIF) assays, plaques of
DEV-H5(UL55) F20 reacted strongly with the mixture of
monoclonal antibodies against AIV H5N1, generating
intense signals under UV light (488 nm), plaques of the
control DEVC-KCE displayed no signals under the same
conditions (Fig. 5a). In western blotting, although
proteins with molecular masses of approximately 80
kiloDaltons (KDa) were observed in lysates of CEFs
infected with either DEV-H5(UL55) that had been pas-
saged five times (F5) or 20 times (F20), no protein bands
were detected in CEFs infected with DEVC-KCE (Fig. 5b).
The sizes of the detected bands from DEV-H5(UL55) F5
and F20 (80 KDa) were slightly bigger than the estimated
size (68 KDa) based on the primary amino acid
sequences of synthesized HA. A similar phenomenon
was reported in a previous study on DEV v2085_H5 HA
expression and was shown to be related to the HA
protein N-linked glycans [9]. In this study, we confirmed
Fig. 4 Comparison of DEVC-KCEgCR, DEV-H5(UL55), and DEVC-KCE multi-step growth kinetics on CEFs. a Viral titers of infected-cell supernatants.
b Viral titers of cell-associated viruses. Titers were determined as the number of plaque forming units in 0.1 ml of sample in three independent
tests. Average titers were determined at the indicated time points after infection with an MOI of 0.01. Error bars represent the standard deviations
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the robust expression of HA in the recombinant DEV-
H5(UL55) after 20 passages.
Safety and immunogenicity of DEV-H5(UL55) in ducks
To test the safety of DEV-H5(UL55) and its efficacy
against virulent DEV, ducks in groups A-DP(5D) and B-
DP(5D) were inoculated intramuscularly with 1 × 106
TCID50 DEV-H5(UL55) virus and DEV vaccine (NJTB),
respectively, and ducks in groups C-DP(5D) (challenge
control) and D-DP(5D) (placebo control) were inocu-
lated intramuscularly with phosphate-buffered saline
(PBS) as controls. All of the ducks in groups A-DP(5D),
B-DP(5D), and C-DP(5D) were challenged with 100
LD50 virulent DEV. No clinical signs were observed in
any of the ducks in group A-DP(5D). From day 3 post-
challenge (d.p.c.), ducks in group C-DP(5D) began to
show symptoms of duck plague, including elevation of
feathers, lethargy, loss of appetite, greenish or water-like
diarrhea, and tremors of necks. Dead ducks were
observed from 4 d.p.c. At the end of the test, 9/10 of the
ducks in group C-DP(5D) died from duck plague,
whereas all the ducks in groups A-DP(5D), B-DP(5D),
and D-DP(5D) were healthy throughout the observation
period (Fig. 6). These results suggest that a single
injection of the virus rescued from the constructed BAC
provides the same strong immunity against duck plague
as vaccination with its parental virus. Moreover, these
results further confirm that the constructed DEV BAC
in this study contains the whole genome of the parental
virus and that the insertion of the synthesized HA
expression cassette into the DEV BAC did not affect its
immunity against duck plague. They also show that the
resulting recombinant DEV-H5(UL55) is safe in ducks.
To further test the safety of DEV-H5(UL55) and to test
its immunogenicity against AI, ducks in groups A-AI(2D),
B-AI(2D), and C-AI(2D) were vaccinated intramuscularly
with DEV-H5(UL55) at a dose of 1 × 107, 1 × 106, and
1 × 105 TCID50, respectively. Birds in group D-AI(2D)
were inoculated twice subcutaneously with inactivated
AIV H5N1 Re-6 vaccine (QYH). Birds in the control
group E-AI(2D) were inoculated with PBS. No clinical
signs were observed in ducks from any of the groups, and
no HI antibodies were detected in any of the ducks in
group E-AI(2D). No HI antibodies were detected in any of
the ducks in groups A-AI(2D), B-AI(2D), and C-AI(2D)
until 4 weeks post-inoculation. At as late as 5 weeks post-
inoculation, a HI titer of 5 log2 was detected in only one
of the 10 ducks in group B-AI(2D). Although HI titers of
2–7 log2 were detected in four of the 10 ducks in group
B-AI(2D) and three of the 10 ducks in group C-AI(2D) at
6 weeks post-inoculation, no HI antibodies were observed
in any of the remaining ducks in these two groups nor
was any detected in the ducks in group A-AI(2D). Mean-
while, in group D-AI(2D), an average HI titer of as high as
8.5 log2 was detected at 1 week after the boost vaccination
with the inactivated vaccine (Fig. 7). These results indicate
that DEV-H5(UL55) stimulated only a weak humoral
immunity against HA(H5N1) in commercial ducks.
This phenomenon was also observed in a previous study
on a DEV-vectored HA(H5N1) vaccine (rDEV-us78HA),
which was generated with the insertion of a HA expression
cassette, composed of the SV40 promoter and the HA from
Fig. 5 IIF and western blotting analysis of DEV-H5(UL55) HA expression. a IIF was performed with a mixture of AIV H5N1 monoclonal antibodies.
Images of DEVC-KCE (lower) and DEV-H5(UL55) F20 (upper) are shown under UV excitation (left) and in phase contrast (right). Each individual panel
represents a view of 200 × 200 μm in size. b Western blotting of HA expression of DEV-H5(UL55). Lane C: lysates of CEFs infected with DEVC-KCE.
Lanes 1 and 2: lysates of CEFs infected with DEV-H5(UL55) F5 and F20, respectively. Proteins were separated by SDS-10 % polyacrylamide gel
electrophoresis and transferred to nitrocellulose membranes (Merck). A mixture of H5 monoclonal antibodies (Genescript) were used as the
primary antibodies and a 1:10,000 dilution of goat-anti-mouse IgG (ABcom) was used as the secondary antibody. Detection was performed with
enhanced chemiluminescence (Sigma-Aldrich). Lane M: DNA marker (PageRulerTM Plus, Fermentas)
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H5N1 AIV AH/1, into the noncoding area between ORF
US7 and US8. An HI titer of as low as 3 ~ 4 log2 was
detected in specific pathogen-free (SPF) ducks inoculated
with two doses of rDEV-us78HA vaccine separated by a
3-week interval at 4 weeks after inoculation; however,
100 % protection was observed in a challenge test with a
highly pathogenic avian influenza H5N1 subtype virulent
strain (HB/49) [30]. In our study, DEV-H5(UL55) was
constructed with the insertion of a pMCMV promoter and
a consensus HA sequence into the noncoding area between
LORF11 and UL55. Although it was demonstrated that the
protective potency of rDEV-us78HA was not related to the
HI titer elicited by inoculation of the vaccine [30], the low
HI titer will seriously hinder the wide application of the
DEV-vectored H5N1 AIV vaccine because the surveillance
system for the outcome of vaccination strategy depends
largely on the examination of HI titer. Further studies will
be needed to improve this DEV-vectored vaccine in order
to elicit much higher HI titers in ducks in advance of inten-
sive challenge tests with H5N1 AIV.
Safety and immunogenicity of DEV-H5(UL55) for chickens
To test the safety of DEV-H5(UL55) and its efficacy against
virulent DEV, chickens in groups A-AI(1C), B-AI(1C), and
C-AI(1C) were vaccinated intramuscularly with DEV-
H5(UL55) at a dose of 1 × 107, 1 × 106, and 1 × 105 TCID50,
respectively. Chickens in group D-AI(1C) were inoculated
subcutaneously with inactivated AIV H5N1 Re-6 vaccine
(QYH), and chickens in the control group E-AI(1C) were
inoculated with PBS. All 1-week-old SPF chickens were
healthy before inoculation, and no HI antibodies were
detected in any of the serum samples collected prior to
inoculation or in control group E-AI(1C) throughout the
experiment. Starting from 3 days post-immunization
(d.p.i.), all of the chickens in groups A-AI(1C), B-AI(1C),
and C-AI(1C) showed clinical signs of duck plague, such as
greenish diarrhea, slow reaction, lethargy, inability to stand,
and loss of appetite. A total of six, three, and one birds died
between 3 and 10 d.p.i. in groups A-AI(1C), B-AI(1C),
and C-AI(1C), respectively (Fig. 8). Lesions of dead birds
exhibited typical xanthochromia in subcutaneous fat or
gelatinous materials, hemorrhage in proventriculus and
pectoralis muscles, necrotic foci in liver, and renomegaly.
The presence of DEV gC in the liver samples of dead birds
was confirmed by PCR with a pair of specific primers
Fig. 7 HI antibody titers against AIV H5N1 in commercial ducks
vaccinated with DEV-H5(UL55). A total of 50 2-week-old commercial
ducks were randomly divided into five groups of A-AI(2D), B-AI(2D),
C-AI(2D), D-AI(2D), and E-AI(2D). Birds in groups A-AI(2D), B-AI(2D), and
C-AI(2D) were vaccinated intramuscularly with DEV-H5(UL55) at a dose of
1 × 107 TCID50 (Lane: 10
7), 1 × 106 TCID50 (Lane: 10
6) and 1 × 105 TCID50
(Lane: 105), respectively. Birds in group D-AI(2D) were inoculated
subcutaneously with a dose of 0.5 ml and 1 ml of inactivated AIV H5N1
Re-6 vaccine (QYH) at 2 w and 5 w, respectively, according to the
manufacturer’s instructions (Lane: Re-6). Birds in the control group
E-AI(2D) were inoculated with 0.2 ml of PBS (Lane: Control). Serum
samples of all birds were collected prior to inoculation and at 1, 2, 3, 4, 5,
and 6 weeks after vaccination to measure the HI titers, which are
shown here
Fig. 6 Protection efficiency of DEV-H5(UL55) against duck plague. A total of 40 commercial ducks were randomly divided into four groups. Ducks
in groups A-DP(5D) (Column DEV-H5(UL55)) and B-DP(5D) (Column DEV vaccine) were inoculated intramuscularly with 1 × 106 TCID50 DEV-H5(UL55) virus
and DEV vaccine(NJTB), respectively. Groups C-DP(5D) (challenge control) and D-DP(5D) (placebo control) were inoculated intramuscularly with 0.2 ml of
PBS as controls. All of the ducks in groups A-DP(5D), B-DP(5D), and C-DP(5D) were challenged with virulent DEV at a dose of 100 LD50 and monitored daily
for 14 days. The survival rates of these four groups at the end of the 14 days are shown here
Wang et al. Virology Journal  (2015) 12:126 Page8of14
(DEV gC flanking F and DEV gC flanking R). Birds in
groups D-AI(1C) and E-AI(1C) were healthy throughout
the experiment (Fig. 8). Results from the HI antibody test
showed that the birds in groups A-AI(1C), B-AI(1C), and
C-AI(1C) developed immune responses no later than
2 weeks post-inoculation with the DEV-vectored vaccine,
whereas no HI antibodies were detected in the samples
from birds in group D-AI(1C). At 3 weeks post-
inoculation, the average peak HI titers were 6.6, 5.6, and
5.5 log2 in the surviving birds in groups A-AI(1C), B-
AI(1C), and C-AI(1C), respectively. Meanwhile, a HI titer
of 7.6 log2 was detected in group D-AI(1C).
To further test the safety of DEV-H5(UL55) and to test
its immunogenicity against AI, 3-week-old chickens in
groups A-AI(3C), B-AI(3C), and C-AI(3C) were vaccinated
intramuscularly with DEV-H5(UL55) at a dose of 1 × 107,
1 × 106, and 1 × 105 TCID50, respectively. Chickens in group
D-AI(3C) were inoculated subcutaneously with inactivated
AIV H5N1 Re-6 vaccine (QYH), and chickens in the
control group E-AI(3C) were inoculated with PBS. The
chickens in all groups were healthy throughout the experi-
ment. At only 1 week post-inoculation, HI antibodies were
detected in two or three birds in groups A-AI(3C), B-
AI(3C), and C-AI(3C), whereas no HI antibodies were
detected in any of the birds in group D-AI(3C). At 4 weeks
post-inoculation, HI titers in groups A-AI(3C), B-AI(3C),
and C-AI(3C) peaked 6.9, 8.3, and 6.3 log2, respectively,
which were higher than the average titer of 6.1 log2 in the
birds in group D-AI(3C) (Fig. 9). These results demonstrate
that DEV-H5(UL55) induced efficient immunity (both
cellular and humoral immunity) against AIV more quickly
compared with the inactivated vaccine. However, this virus
showed virulence for young chickens. The parental virus,
C-KCE strain, was isolated from liver samples from ducks
that died of duck plague and was attenuated through serial
passages in chick embryos [5, 30]. This process might
increase the virulence of viruses for young chickens. Never-
theless, the robust immunity induced in chickens might be
due to the efficient replication of the virus after inoculation.
While the induction of high HI titers in chickens
inoculated with DEV-H5(UL55) provides strong evi-
dence for its ability to activate humoral immunity,
the high HI titers induced in ducks vaccinated with
an inactivated AIV vaccine exclude the possibility that
ducks have an inherently low reaction to AIV HA as
an antigen. A possible explanation for the extremely
weak HI titers in ducks inoculated with DEV-
H5(UL55) might be that DEV interferes with duck
immunity. It is known that some herpesvirus proteins
can interfere with the host immune reaction. This
interference is an important mechanism of interaction
between viruses, such as Marek’s disease virus and
herpes simplex virus, and their hosts during evolution
[33, 34]. This phenomenon might also hold true for
DEV-vectored vaccines. Furthermore, the vaccination
strategy for control of AIV H5N1 in many countries,
including China, depends on a reliable detection
method to evaluate the efficacy of vaccination. The
improved ability of DEV-H5(UL55) to induce a much
higher HI titer in ducks is a prerequisite for the wide
application of this DEV-vectored vaccine. Future studies
might include deletion or modification of suspected im-
mune interference related genes in the DEV-vectored
vaccine.
Fig. 8 Safety of DEV-H5(UL55) for chickens. A total of 50 1-week-old SPF chickens were randomly divided into five groups of A-AI(1C), B-AI(1C),
C-AI(1C), D-AI(1C), and E-AI(1C). In groups A-AI(1C), B-AI(1C), and C-AI(1C), chickens were vaccinated intramuscularly with DEV-H5(UL55) at a dose
of 1 × 107 TCID50 (Line 10
7), 1 × 106 TCID50 (Line: 10
6), and 1 × 105 TCID50 (Line: 10
5), respectively. Chickens in group D-AI(1C) were inoculated
subcutaneously with a dose of 0.3 ml of inactivated AIV H5N1 Re-6 vaccine (QYH) (Line: Re-6). Chickens in the control group E-AI(1C) were
inoculated with 0.2 ml PBS (Line: Control). All birds were observed for clinical signs over the 14 days after inoculation. The survival rates of these
five groups over the 14 days are shown here
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Conclusions
In this study, an infectious clone of DEV vaccine strain
C-KCE was successfully constructed with the insertion
of mini-F sequences in lieu of gC. Growth kinetics,
RFLP, and animal tests of gC-recovered viruses or
BACs were performed to show that this clone consists
of the whole C-KCE strain genome. Further, a DEV-
vectored vaccine harboring a synthesized HA expres-
sion cassette between the ORF of UL55 and LORF11
was efficiently generated through the En Passant proto-
col based on this infectious clone. Additionally, animal
tests showed that this DEV-vectored vaccine was safe
in ducks and that one dose of the vaccine provided 100 %
protection against duck plague. Although one dose of the
vaccine induced high HI titers (8.3 log2) against AIV
H5N1 in 3-week-old commercial layer chickens, it only
stimulated weak HI titers in commercial ducks. Moreover,
the DEV-vectored vaccine was virulent in young chickens.
Future studies that include the deletion or modification of
genes associated with immune regulation and virulence
will be required prior to any wide application of the DEV-
vectored HA(H5) vaccine. Once this vaccine has been
modified to induce a higher HI titer, challenge tests to
evaluate its ability to protect against AI will be carried out
with homogeneous or heterogeneous viruses of AIV H5N1.
Methods
Viruses and plasmids
A DEV attenuated strain (C-KCE strain, DEVC-KCE), the
widely used commercial vaccine strain attenuated by serial
passaging in SPF chicken embryonated eggs, was isolated
from a batch of commercial vaccine provided by the Nan-
jing Tech-bank Bio-industry Co., Ltd. (Nanjing, China) and
then purified through three rounds of plaque picking. DEV
virulent virus was obtained from the China Veterinary Cul-
ture Collection Management Center. All DEV strains were
propagated on primary or secondary CEFs. Virus stocks
were prepared from CEF cultures, which were infected
with viruses at a multiplicity of infection (MOI) of 0.01 and
cultured for 72 h. Viruses were released by three freeze-
th–w cycles (−70 °C and 37 °C) and stored at −70 °C for
further use. Pfu or TCID50 titers were determined on CEFs
according to the standard titration method [9, 31]. The
BAC transfer vector plasmid pDEVgc-pHA2 was kindly
provided by professor Niklaus Osterrieder from the Free
University of Berlin [9]. The HA expression cassette con-
taining a pMCMV IE promoter and a consensus HA gene
(GenBank: KP019932) was synthesized and cloned into T-
Vector pMD19 (Simple; Takara, Otsu, Japan) with slight
modification to generate the plasmid pDEV-H5(UL55).
Briefly, the HA gene was artificially synthesized based
on a consensus sequence of the most updated HA genes
of AIV clade 2.3.2.1 (GenBank: AB700635.1; JN986881.1;
JN986882.1; JN646713.1; JN646716.1; HQ020376.1; CY09
8758.1; and JF975561.1) with a deletion of four basic
amino acids at the cleavage site, as described previously
[30]. The promoter pMCMV IE included a sequence
complementary to the sequence between site 184336 and
182946 in the MCMV genome of (GenBank: GU305914.1)
followed by a Kozak sequence. The plasmid pDEV-
H5(UL55) KANin containing the HA expression cassette
and a kanamycin resistance gene inserted at the Sac I
restriction site was constructed by cutting and ligating
for further En Passant recombination (Fig. 3).
Cells, viral DNA extraction, and transfection
CEFs were propagated in Earle’s minimal essential medium
(EMEM; Gibco, Los Angeles, CA USA) supplemented with
Fig. 9 HI antibody titers against AIV H5N1 in chickens vaccinated with DEV-H5(UL55). A total of 50 3-week-old commercial chickens were
randomly divided into five groups of A-AI(3C), B-AI(3C), C-AI(3C), D-AI(3C), and E-AI(3C). In groups A-AI(3C), B-AI(3C), and C-AI(3C), chickens were
vaccinated intramuscularly with DEV-H5(UL55) at a dose of 1 × 107 TCID50 (Line: 10
7), 1 × 106 TCID50 (Line: 10
6), and 1 × 105 TCID50 (Line: 10
5),
respectively. Chickens in group D-AI(3C) were inoculated subcutaneously with a dose of 0.3 ml of inactivated AIV H5N1 Re-6 vaccine (QYH)
according to the manufacturer’s instructions (Line: Re-6). Chickens in the control group E-AI(3C) were inoculated with 0.2 ml of PBS (Line: Control).
Serum samples of all chickens were collected before inoculation and at 1, 2, 3, 4, 5, and 6 weeks after vaccination to measure the HI titers, which
are shown here
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10 % newborn calf serum (NBCS; Gibco), 100 U/ml penicil-
lin, and 100 μg/ml streptomycin at 37 °C under a 5 % CO2
atmosphere. Viral DNA was purified from infected cells by
sodium dodecyl sulfate (SDS)-proteinase K extraction as
described previously [35]. The transfection of DNA from
plasmids, viruses, or BACs was achieved by calcium
phosphate precipitation [35]. Briefly, approximately 200 ng
DNA was mixed with water, and then 62 μl 2 M CaCl2 was
added dropwise to a total volume of 500 μl. The trans-
fection mixture was incubated over night at 4 °C followed
by the addition of 500 μl cold 2 ×HEPES-bufftered
saline(HBS) solution dropwise. The medium in each well
was replaced with 500 μl of fresh EMEM without NBCS
or antibiotics and incubated with the transfection mixture
at 37 °C for 3–4 h. Media were discarded and the plate
was washed twice with PBS. 1.5 ml 15 % glycerol HBS so-
lution was added to each well and the plate was incubated
for 2 min. The transfection solution was replaced with
EMEM supplemented with 10 % NBCS and antibiotics,
after washing twice with PBS, for culture at 37 °C in an in-
cubator with 5 % CO2.
Multi-step growth kinetics
The growth characteristics of viruses were tested on
primary or secondary CEFs with an MOI of 0.01 as
described previously with a slight modification [9]. Briefly,
the virus titers of the supernatant- and cell-associated
viruses were checked at 0, 6, 12, 24, 36, 48, and 72 h p.i. for
parental virus and mutants. For cell-associated viruses,
infected cells were washed twice with PBS at each indicated
time point and resuspended in 2 ml of EMEM for three
freeze–thaw cycles to release viruses. Virus titers were
tested following the standard pfu titration method [9] after
removal of cellular residue by centrifugation at 500 × g for
10 min. To measure the titer of viruses in the supernatants,
the supernatants of infected cell cultures were sampled at
the indicated time points and titrated after removal of cellu-
lar debris by centrifugation. The growth kinetics curve was
established based on data in three independent experi-
ments, and the differences of titers at 48 h and 72 h p.i.
were statistically analyzed by one-way analysis of variance
(SPSS software package) [9].
Bacterial manipulations
Electrocompetent E. coli cells were obtained from a com-
mercial supplier (DH10B, Invitrogen) or prepared in our
lab following previously described protocols [9] and
GS1783, which was kindly provided by professor Nikolaus
Osterrieder [9]. Electroporation was conducted exactly as
described previously [36, 37]. Commercial chemical-
competent E. coli cells DH5α (Takara) were used for chem-
ical transformation of plasmid DNA as previously described
[9]. DNA from the BAC or plasmid was prepared with a
PureLink® Quick Plasmid Miniprep Kit (Invitrogen) and a
Large–Construct Kit for midi-prep (Qiagen) according to
the manufacturer’s instructions.
PCR, restriction analysis, and sequencing
For the insertion of a kanamycin resistance gene into
plasmid pDEV-H5(UL55), a pair of specific primers (Kan
ins’ H5(HA) F and Kan ins’ H5(HA); Table 1) were
designed with two Sac I restriction sites added to both
terminals for cutting and ligation. The construct was
examined by digestion with Hind III to check the correct
insertion of the kanamycin resistance gene. Another pair
of primers (DEV ins H5 casse UL55 F and DEV ins H5
casse UL55 R; Table 1) were used for insertion of the
HA cassette into the DEV BAC clone through the En
Passant protocol. To repair the gC genes of the gC-
negative virus, a pair of primers (DEV gC flanking F and
DEV gC flanking R; Table 1) were used to amplify a
fragment that included the gC gene and two homolo-
gous 1 kpb flanking sequences of gC. The construct was
sequenced using 20 specific primers (Table 1) to verify
the sequence of the inserted HA expression cassette.
The BACs and mutants were subjected to RFLP analysis
with EcoR I and BamH I, performed as described previ-
ously [9].
Generation of a DEVC-KCE infectious clone
A DEVC-KCE infectious clone was generated with a method
modified from the generation of BAC from the DEV 2085
strain [9]. Briefly, co-transfection of DNA from DEVC-KCE
and pDEVgc-pHA2 was conducted on primary CEFs (24 h)
to allow for an insertion of mini-F sequences in lieu of gC.
After green plaques were observed under UV light
(488 nm), a homogeneous population of mini-F recombin-
ant DEVC-KCE (DEVC-KCE-miniF) was obtained by three
rounds of picking and plating on CEFs and transferred into
E. coli DH10B competent cells (Invitrogen) by electropor-
ation. Positive clones with chloramphenicol resistance were
examined through RFLP with EcoR I and BamH I to select
a clone of DEVC-KCE, which was then electroporated into E.
coli GS1783 [9] for further genetic manipulation of the
DEV genome. The resulting clone (pDEVC-KCE) was
confirmed through RFLP. Next, gC was restored by
homologous recombination as described previously [9].
A homogenous population of gC-recovered virus
(DEVC-KCEgCR) was purified by picking and plating of
the nonfluorescent plaques under UV light (488 nm)
and verified by PCR and sequencing using a pair of
primers (DEV gC flanking F and DEV gC flanking R;
Table 1).
Construction of a DEV-vectored HA
An HA expression cassette was inserted into the non-
coding area between the ORFs UL55 and LORF11 in
the DEV BAC clone pDEVC-KCE genome to replace
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the nucleotide fragments between sites 263 and 291
(GenBank ID: EU082088.2) through the En Passant
method [32] with minor modifications. Briefly, PCR
was performed using plasmid pDEV-H5(UL55) KANin
DNA as a template, and a pair of primers (DEV ins H5
casse UL55 F and DEV ins H5 casse UL55 R) to amplify
the HA cassette with 40 bp homologous sequences flank-
ing both terminals. After digestion with Dpn I to get rid of
possible plasmid pollution, the PCR product was electro-
porated into competent pDEVC-KCE cells to generate the
first recombination with the cassette at the indicated sites.
The target recombinant pDEVC-KCE-H5(UL55)-vectored
HA clone was generated by deletion of the kanamycin
resistance gene by the second recombination (Fig. 3).
Selected clones without kanamycin resistance were con-
firmed by RFLP with EcoR I and BamH I. The DEVC-KCE-
vectored HA, termed DEV-H5(UL55), was generated with
gC recovered in a way similar to that of DEVC-KCEgCR.
The DEVC-KCE-H5(UL55) HA expression cassette was
amplified by PCR (primers: DEV ins H5 casse UL55 F
and DEV ins H5 casse UL55 R) and confirmed by se-
quencing with 20 specific sequencing primers (Table 1).
DEV-H5(UL55) was subsequently cultured on CEFs for
20 generations to check the stability of the recombinant
virus. F20 virus DNA was isolated for sequencing the
HA expression cassette.
IIF and western blotting
The expression DEV-vectored HA was examined by IIF
and western blotting as previously described [9]. For IIF,
DEV-H5(UL55) F20 was inoculated onto primary or sec-
ondary CEFs with a ratio of 50–100 pfu per well on a six-
well plate. At 48 h after inoculation, the infected cells were
fixed with cold fixing solution (ethanol (96 %): acetone =
3:1) for 20 min at −20 °C. The fixing solution wad dis-
carded, and the cells were washed once with PBS and then
permeabilized in PBS with 0.1 % Triton X-100 for 5 min.
After fixation, a PBS solution with 3 % BSA was added to
block the sample wells for 1 h or overnight. A mixture
of monoclonal antibodies against AIV H5N1 HA
(Genescript, Nanjing, China) was added and the sam-
ples were incubated for 1 h at room temperature. Each
well was washed three times with PBS, a 1:2000 solu-
tion of goat-anti-mouse IgG antibodies conjugated with
Table 2 Groups of animals tested to evaluate the safety, efficacy, and immunogenicity of DEV-H5(UL55)
Group Vaccine or PBS Dose Animal/age
A-DP(5D) DEV-H5(UL55) 1 × 106 TCID50, 0.2 mL Ducks/5w
a
B-DP(5D) DEV vaccine 1 × 106 TCID50, 0.2 mL Ducks/5w
C-DP(5D) PBS 0.2 mL Ducks/5w
D-DP(5D) PBS 0.2 mL Ducks/5w
A-AI(2D) DEV-H5(UL55) 1 × 107 TCID50, 0.2 mL Ducks/2w
b
B-AI(2D) DEV-H5(UL55) 1 × 106 TCID50, 0.2 mL Ducks/2w
C-AI(2D) DEV-H5(UL55) 1 × 105 TCID50, 0.2 mL Ducks/2w
D-AI(2D) Inactivated AI(H5N1) Re-6 vaccine 0.5 mL and 1 mL at 2w and 5w respectively Ducks/2w
E-AI(2D) PBS 0.2 mL Ducks/2w
A-AI(1C) DEV-H5(UL55) 1 × 107 TCID50, 0.2 mL SPF chickens/1w
c
B-AI(1C) DEV-H5(UL55) 1 × 106 TCID50, 0.2 mL SPF chickens/1w
C-AI(1C) DEV-H5(UL55) 1 × 105 TCID50, 0.2 mL SPF chickens/1w
D-AI(1C) Inactivated AI(H5N1) Re-6 vaccine 0.3 mL SPF chickens/1w
E-AI(1C) PBS 0.2 mL SPF chickens/1w
A-AI(3C) DEV-H5(UL55) 1 × 107 TCID50, 0.2 mL Layers/3w
d
B-AI(3C) DEV-H5(UL55) 1 × 106 TCID50, 0.2 mL Layers/3w
C-AI(3C) DEV-H5(UL55) 1 × 105 TCID50, 0.2 mL Layers/3w
D-AI(3C) Inactivated AI(H5N1) Re-6 vaccine 0.3 mL Layers/3w
E-AI(3C) PBS 0.2 mL Layers/3w
aA total of 40 5-week-old commercial ducks were randomly divided into four groups of A-DP(5D), B-DP(5D), C-DP(5D), and D-DP(5D) to test the safety and
protection efficiency of DEV-H5(UL55) against virulent DEV challenge
bA total of 50 2-week-old commercial ducks were randomly divided into five groups of A-AI(2D), B-AI(2D), C-AI(2D), D-AI(2D), and E-AI(2D) to test of safety and
potency of DEV-H5(UL55) in stimulation of HI antibodies against AI(H5N1), compared with inactivated AI(H5N1) Re-6 vaccine
cA total of 50 1-week-old SPF chickens were randomly divided into five groups of A-AI(1C), B-AI(1C), C-AI(1C), D-AI(1C), and E-AI(1C) to test the safety and potency
of DEV-H5(UL55) in the stimulation of HI antibodies against AI(H5N1)
dA total of 50 3-week-old commercial layer chickens were randomly divided into five groups of A-AI(3C), B-AI(3C), C-AI(3C), D-AI(3C), and E-AI(3C) to test the safety
and potency of DEV-H5(UL55) in the stimulation of HI antibodies against AI(H5N1)
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Alexa488 (Invitrogen) was added, and the samples were
incubated for 1 h, then observed under UV light
(488 nm).
For western blotting, CEFs were infected with F5 or
F20 DEV-H5(UL55) viruses with an MOI of 0.01. In-
fected cells were lysed and cell lysates were denatured by
heating at 95 °C for 10 min. Proteins were separated by
SDS-10 % polyacrylamide gel electrophoresis (PAGE),
and then transferred to nitrocellulose membranes
(Merck) as described previously [11]. A mixture of H5
monoclonal antibodies (Genescript) was used as the pri-
mary antibodies for western blotting and a 1:10,000 dilu-
tion of goat-anti-mouse IgG (ABcom) was used as the
secondary antibody. DEVC-KCE-infected CEFs were used
as a control. Samples were detected with enhanced
chemiluminescence (Sigma-Aldrich).
Safety and immunogenicity of DEV-vectored HA in ducks
and chickens
For the duck plague protection test, a total of 40 com-
mercial ducks (5 weeks old) were randomly divided into
four groups (Table 2). Ducks in groups A-DP(5D) and
B-DP(5D) were inoculated intramuscularly with DEV-
H5(UL55) virus and DEV vaccine (commercial product
from Nanjing Tech-bank Bio-industry Co., Ltd), respect-
ively, each at a dose of 1 × 106 TCID50. Ducks in groups
C-DP(5D) and D-DP(5D) were inoculated intramuscu-
larly with 0.2 ml of PBS as controls. Three weeks after
inoculation, all the groups except group D-DP(5D) were
challenged with virulent DEV at a dose of 100 LD50 and
observed daily for 14 days to analyze the morbidity and
mortality.
To assess the immunogenicity of the DEV-vectored
HA against AIV in ducks, 50 ducks (2 weeks old) were
randomly divided into five groups: A-AI(2D), B-AI(2D),
C-AI(2D), D-AI(2D), and E-AI(2D) (Table 2). Ducks in
groups A-AI(2D), B-AI(2D), and C-AI(2D) were vacci-
nated intramuscularly with DEV-H5(UL55) at a dose of
1 × 107, 1 × 106, and 1 × 105 TCID50, respectively. Ducks
in group D-AI(2D) were inoculated subcutaneously with
0.5 ml and 1 ml inactivated AIV H5N1 Re-6 vaccine
from a commercial supplier (QYH, Zhengzhou, China)
at 2 and 5 weeks of age, respectively. Ducks in the con-
trol group E-AI(2D) were inoculated with 0.2 ml of PBS.
Serum samples from all ducks were collected prior to in-
oculation and at 1, 2, 3, 4, 5, and 6 weeks post-
immunization to test the HI titers with kits (HWBD,
Harbin China) following the manufacturer’s instructions.
To evaluate the safety and immunogenicity of the
DEV-vectored HA against AIV for chickens, the HI anti-
body levels were assessed in 50 1-week-old SPF chickens
and 50 3-week-old commercial layer chickens (Table 2).
SPF chickens were randomly divided into five groups: A-
AI(1C), B-AI(1C), C-AI(1C), D-AI(1C), and E-AI(1C).
Commercial layer chickens were also divided into five
groups: A-AI(3C), B-AI(3C), C-AI(3C), D-AI(3C), and E-
AI(3C). In groups A-AI(1C)/A-AI(3C), B-AI(1C)/B-
AI(3C), and C-AI(1C)/C-AI(3C), chickens were vaccinated
intramuscularly with DEV-H5(UL55) at a dose of 1 × 107,
1 × 106, and 1 × 105 TCID50, respectively. Chickens in
groups D-AI(1C)/D-AI(3C) were inoculated subcutane-
ously with 0.3 ml of inactivated AIV H5N1 Re-6 vaccine
(QYH) according to the manufacturer’s instructions.
Chickens in control groups E-AI(1C)/E-AI(3C) were inoc-
ulated with 0.2 ml of PBS. Serum samples from all chick-
ens were collected prior to inoculation and at 1, 2, 3, 4, 5,
and 6 weeks post-vaccination and the HI titers of these
samples were measured. All birds were monitored for
clinical signs throughout the experiments.
All animal studies were approved by the Institutional
Animal Care and Use Committee and were conducted
following the guidelines of the Institutional Biosafety
Committee at the Jiangsu Academy of Agriculture Sci-
ences. Experiments involving virulent DEV were con-
ducted under Biosafety Level 2+ containment.
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